News
Public · Published
TD Cowen maintains Twist Bioscience at Buy, lowers price target to $137 from $190
TD Cowen kept its Buy rating on Twist Bioscience but cut its price target to $137 from $190, a 27.9% decrease. The new target implies 19.9% upside from the November 12 closing price of $114.22.
Published:
Updated:
What happened
TD Cowen kept its Buy rating on Twist Bioscience but cut its price target to $137 from $190, a 27.9% decrease. The new target implies 19.9% upside from the November 12 closing price of $114.22.
Confirmed
Global impact / market context
The lower target signals that TD Cowen now sees less potential value in Twist Bioscience shares than before, while its unchanged Buy rating still indicates a favorable view. Investors may weigh that change against the stated 19.9% implied upside from the cited closing price.
Analyst inference
This is an analyst forecast, not a reported change in Twist Bioscience’s sales, costs, or cash available. The target is 19.9% above the cited close, but the reduction from $190 shows TD Cowen’s estimate has become more cautious.
Analyst inference
What to watch
- Watch for later changes to TD Cowen’s rating or target; the article reports only the current Buy rating and the reduction to $137. Analyst inference
- Compare future company results with the expectations behind the $137 target; the supplied article gives no reasons for the reduction or operating forecasts. Analyst inference
- Track whether the stated 19.9% implied upside changes as the share price moves, since it is calculated from the November 12 close of $114.22. Analyst inference
Evidence
- Original source link unavailable